SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001346302-21-000052
Filing Date
2021-06-08
Accepted
2021-06-08 16:52:31
Documents
13
Period of Report
2021-06-08
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K xers-20210608.htm   iXBRL 8-K 41161
  Complete submission text file 0001346302-21-000052.txt   215338

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xers-20210608.xsd EX-101.SCH 2165
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT xers-20210608_def.xml EX-101.DEF 15623
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xers-20210608_lab.xml EX-101.LAB 30040
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xers-20210608_pre.xml EX-101.PRE 16292
6 EXTRACTED XBRL INSTANCE DOCUMENT xers-20210608_htm.xml XML 11507
Mailing Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601
Business Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601 844-445-5704
XERIS PHARMACEUTICALS INC (Filer) CIK: 0001346302 (see all company filings)

IRS No.: 203352427 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38536 | Film No.: 211002729
SIC: 2834 Pharmaceutical Preparations